GV20 Therapeutics
Overview
We utilize high throughput functional genomics and AI approaches to identify novel cancer immunology drug targets, and discover and develop effective antibody drugs in cancer. GV20.
Funding and backers
Backers
1
Coatue
Momentum
0/100
no fresh signals
Backed byfrom the funds' portfolios and accelerator catalogs
Coatue Investors in similar startupsfunds that back the companies most like this one
backs Simmunome Inc.
backs Antiverse
Similar startupsby what they do, their industry and backers
Closing the Translational Gap in Inflammation and Immunology drug discovery A.
Antiverse combines generative AI and advanced antibody discovery to design functional, developable biologics for challenging drug targets.
Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need…
Novel ADC Payloads for Cancer Hexagon Bio is developing novel payload mechanisms for antibody-drug conjugates (ADCs) to overcome resistance…
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality.
Simmunome offers a genAI platform that utilizes mechanistic modeling combined with machine learning to simulate the efficacy and safety of…
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely